Vermillion, Quest Ink Deal to Sell OVA1 in India
April 04, 2011
Vermillion, Quest Ink Deal to Sell OVA1 in India
With the launch, expected in the second quarter, "Vermillion is now poised for growth both domestically and internationally as we continue to develop our international strategy in concert with the efforts already underway in the US," its CEO said.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Vermillion and Quest Sign Deal to Offer OVA1 in India
April 8, 2011 / ProteoMonitor - Vermillion Plans to Raise Up to $17.3M in Stock Offering
January 21, 2011 / ProteoMonitor - Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test
January 14, 2011 / ProteoMonitor - Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance
November 12, 2010 / ProteoMonitor - Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor